Cargando…

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

AIMS: To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). METHODS AND RESULTS: We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from...

Descripción completa

Detalles Bibliográficos
Autores principales: Ference, Brian A., Ginsberg, Henry N., Graham, Ian, Ray, Kausik K., Packard, Chris J., Bruckert, Eric, Hegele, Robert A., Krauss, Ronald M., Raal, Frederick J., Schunkert, Heribert, Watts, Gerald F., Borén, Jan, Fazio, Sergio, Horton, Jay D., Masana, Luis, Nicholls, Stephen J., Nordestgaard, Børge G., van de Sluis, Bart, Taskinen, Marja-Riitta, Tokgözoğlu, Lale, Landmesser, Ulf, Laufs, Ulrich, Wiklund, Olov, Stock, Jane K., Chapman, M. John, Catapano, Alberico L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837225/
https://www.ncbi.nlm.nih.gov/pubmed/28444290
http://dx.doi.org/10.1093/eurheartj/ehx144
_version_ 1783304080169369600
author Ference, Brian A.
Ginsberg, Henry N.
Graham, Ian
Ray, Kausik K.
Packard, Chris J.
Bruckert, Eric
Hegele, Robert A.
Krauss, Ronald M.
Raal, Frederick J.
Schunkert, Heribert
Watts, Gerald F.
Borén, Jan
Fazio, Sergio
Horton, Jay D.
Masana, Luis
Nicholls, Stephen J.
Nordestgaard, Børge G.
van de Sluis, Bart
Taskinen, Marja-Riitta
Tokgözoğlu, Lale
Landmesser, Ulf
Laufs, Ulrich
Wiklund, Olov
Stock, Jane K.
Chapman, M. John
Catapano, Alberico L.
author_facet Ference, Brian A.
Ginsberg, Henry N.
Graham, Ian
Ray, Kausik K.
Packard, Chris J.
Bruckert, Eric
Hegele, Robert A.
Krauss, Ronald M.
Raal, Frederick J.
Schunkert, Heribert
Watts, Gerald F.
Borén, Jan
Fazio, Sergio
Horton, Jay D.
Masana, Luis
Nicholls, Stephen J.
Nordestgaard, Børge G.
van de Sluis, Bart
Taskinen, Marja-Riitta
Tokgözoğlu, Lale
Landmesser, Ulf
Laufs, Ulrich
Wiklund, Olov
Stock, Jane K.
Chapman, M. John
Catapano, Alberico L.
author_sort Ference, Brian A.
collection PubMed
description AIMS: To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). METHODS AND RESULTS: We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. CONCLUSION: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
format Online
Article
Text
id pubmed-5837225
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58372252018-03-09 Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel Ference, Brian A. Ginsberg, Henry N. Graham, Ian Ray, Kausik K. Packard, Chris J. Bruckert, Eric Hegele, Robert A. Krauss, Ronald M. Raal, Frederick J. Schunkert, Heribert Watts, Gerald F. Borén, Jan Fazio, Sergio Horton, Jay D. Masana, Luis Nicholls, Stephen J. Nordestgaard, Børge G. van de Sluis, Bart Taskinen, Marja-Riitta Tokgözoğlu, Lale Landmesser, Ulf Laufs, Ulrich Wiklund, Olov Stock, Jane K. Chapman, M. John Catapano, Alberico L. Eur Heart J Current Opinion AIMS: To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). METHODS AND RESULTS: We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. CONCLUSION: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD. Oxford University Press 2017-08-21 2017-04-24 /pmc/articles/PMC5837225/ /pubmed/28444290 http://dx.doi.org/10.1093/eurheartj/ehx144 Text en © The Author 2017. Published on behalf of the European Society of Cardiology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Current Opinion
Ference, Brian A.
Ginsberg, Henry N.
Graham, Ian
Ray, Kausik K.
Packard, Chris J.
Bruckert, Eric
Hegele, Robert A.
Krauss, Ronald M.
Raal, Frederick J.
Schunkert, Heribert
Watts, Gerald F.
Borén, Jan
Fazio, Sergio
Horton, Jay D.
Masana, Luis
Nicholls, Stephen J.
Nordestgaard, Børge G.
van de Sluis, Bart
Taskinen, Marja-Riitta
Tokgözoğlu, Lale
Landmesser, Ulf
Laufs, Ulrich
Wiklund, Olov
Stock, Jane K.
Chapman, M. John
Catapano, Alberico L.
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
title Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
title_full Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
title_fullStr Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
title_full_unstemmed Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
title_short Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
title_sort low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. evidence from genetic, epidemiologic, and clinical studies. a consensus statement from the european atherosclerosis society consensus panel
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837225/
https://www.ncbi.nlm.nih.gov/pubmed/28444290
http://dx.doi.org/10.1093/eurheartj/ehx144
work_keys_str_mv AT ferencebriana lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT ginsberghenryn lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT grahamian lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT raykausikk lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT packardchrisj lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT bruckerteric lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT hegeleroberta lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT kraussronaldm lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT raalfrederickj lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT schunkertheribert lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT wattsgeraldf lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT borenjan lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT faziosergio lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT hortonjayd lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT masanaluis lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT nichollsstephenj lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT nordestgaardbørgeg lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT vandesluisbart lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT taskinenmarjariitta lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT tokgozoglulale lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT landmesserulf lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT laufsulrich lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT wiklundolov lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT stockjanek lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT chapmanmjohn lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel
AT catapanoalbericol lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel